GlioModel is a collaboration of neuro-oncology research groups from 8 participating UK institutions, each housing one or more glioblastoma (GBM) preclinical models that span a range of in vitro through ex vivo to in vivo experimental systems. We are working together to show how functional assessment of candidate pathogenic molecules or pathways across multiple models can be used to expedite preclinical target validation and give more in depth insight into mechanisms underpinning malignant phenotypes.
In this context models refers not just to specific cell lines but also the mode/environment in which cells are cultured or maintained.
The GlioModel consortium is led by BNOS Research Subcommittee member Dr. Lucy Stead.
